Literature DB >> 11485329

Mice lacking serum amyloid P component do not necessarily develop severe autoimmune disease.

M Soma1, T Tamaoki, H Kawano, S Ito, M Sakamoto, Y Okada, Y Ozaki, S Kanba, Y Hamada, T Ishihara, S Maeda.   

Abstract

Serum amyloid P component (SAP) is a major acute-phase reactant in mice. Recently, it was reported that SAP-deficient mice spontaneously developed anti-nuclear antibodies and severe glomerulonephritis. Because the SAP-deficient mice we generated display no obvious phenotypic abnormalities, we investigated whether our SAP-deficient mice would also spontaneously develop autoimmune responses. In accordance with the report, our mice produced high titers of anti-nuclear antibody but did not develop severe glomerulonephritis. On the other hand, it was recently reported that SAP bound to gram-negative bacteria via lipopolysaccharide (LPS) prevented LPS-mediated activation of a classical complement pathway. Thus, we asked if SAP-deficient mice would show altered responses to an intraperitoneal injection of LPS from Salmonella typhimirium. SAP-deficiency did afford resistance to lethality induced by high-dose LPS. Our experiments clearly showed that contrary to documented data, SAP-deficient mice do not develop serious autoimmune disease and we suggest that SAP has a critical role in LPS toxicity. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485329     DOI: 10.1006/bbrc.2001.5364

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine.

Authors:  Selena Y Lin; Veerpal Dhillon; Surbhi Jain; Ting-Tsung Chang; Chi-Tan Hu; Yih-Jyh Lin; Shun-Hua Chen; Kung-Chao Chang; Wei Song; Lixin Yu; Timothy M Block; Ying-Hsiu Su
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

2.  Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.

Authors:  G Zandman-Goddard; M Blank; P Langevitz; L Slutsky; M Pras; Y Levy; O Shovman; T Witte; A Doria; J Rovensky; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 3.  Pattern recognition by pentraxins.

Authors:  Alok Agrawal; Prem Prakash Singh; Barbara Bottazzi; Cecilia Garlanda; Alberto Mantovani
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

4.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

5.  Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.

Authors:  Karin Andersson; Malgorzata Pokrzywa; Ingrid Dacklin; Erik Lundgren
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

Review 6.  Pentraxins: structure, function, and role in inflammation.

Authors:  Terry W Du Clos
Journal:  ISRN Inflamm       Date:  2013-09-14

7.  Persistent lung inflammation and fibrosis in serum amyloid P component (APCs-/-) knockout mice.

Authors:  Darrell Pilling; Richard H Gomer
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.